CLSD - Clearside Biomedical, Inc.
1.5500 +0.01 (0.65%)
After hours: 5:04PM EDT
| Previous Close | 1.4600 |
| Open | 1.4600 |
| Bid | 1.5000 x 800 |
| Ask | 1.5700 x 900 |
| Day's Range | 1.4500 - 1.5700 |
| 52 Week Range | 0.9900 - 15.3290 |
| Volume | 925,848 |
| Avg. Volume | 1,130,233 |
| Market Cap | 55.5M |
| Beta (3Y Monthly) | -1.10 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.6950 |
| Earnings Date | Mar 15, 2019 - Mar 18, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of CLSD earnings conference call or presentation 12-Mar-19 9:00pm GMT
Q4 2018 Clearside Biomedical Inc Earnings Call
- GlobeNewswire•9 days ago
Clearside Biomedical Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
- Novel Retinal Treatment Demonstrates Potential of Proprietary Therapeutic Platform -- XIPERE™ NDA Accepted and On Track for October 19, 2019 PDUFA Date -- Management to Host.
- GlobeNewswire•17 days ago
Clearside Biomedical to Present at the Cowen and Company 39th Annual Health Care Conference
ALPHARETTA, Ga., March 04, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- GlobeNewswire•22 days ago
Clearside Biomedical to Report 2018 Financial Results and Provide Corporate Update on Tuesday, March 12, 2019
ALPHARETTA, Ga., Feb. 27, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Simply Wall St.•24 days ago
Do Insiders Own Shares In Clearside Biomedical, Inc. (NASDAQ:CLSD)?
Want to participate in a short research study? Help shape the future of investing tools and receive a $20 prize! Every investor in Clearside Biomedical, Inc. (NASDAQ:CLSD) should be awareRead More...
- ACCESSWIRE•29 days ago
Four Tech Stocks Bubbling with Excitement
ParcelPal Technology Inc (PTNYF) (PKG), Clearside Biomedical Inc (CLSD), ACM Research Inc (ACMR), and Everspin Technologies (MRAM) are four tech companies exemplifying what it means to be forward-thinking. ParcelPal Technology Inc (PTNYF) (PKG) was, like many other tech companies, born out of a desire to solve a systemic issue, but where the Company rises above the rest is in their core framework and execution. ParcelPal's founders recognized an apparent need for consumers to have increased access to the products and goods they use on a daily basis, so they created an on-demand marketplace where customers can purchase nearly any product on the market and have it delivered within the hour.
- GlobeNewswire•29 days ago
Recent Analysis Shows Cisco, Zendesk, Clearside Biomedical, Conn's, NIC, and Commercial Vehicle Group Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, Feb. 20, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•29 days ago
Clearside Biomedical Receives Notification of FDA Acceptance of NDA Filing for XIPERE™ (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection with PDUFA Date Set for October 19, 2019
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that it received notification from the U.S. Food and Drug Administration (FDA) that the Agency has accepted for review the New Drug Application (NDA) for XIPERE (triamcinolone acetonide ophthalmic suspension) for Suprachoroidal Injection for the treatment of macular edema associated with uveitis. The FDA has determined that the application is sufficiently complete to permit a substantive review.
- GlobeNewswire•last month
Clearside Biomedical’s Suprachoroidal Injection Platform Featured in Multiple Oral Presentations at 42nd Annual Meeting of The Macula Society
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that multiple oral presentations were given at the 42nd Annual Macula Society Meeting held February 13-16, 2019 in Bonita Springs, Florida. The four scientific presentations reviewed clinical and nonclinical data analyses of Clearside programs in multiple disease states, including macular edema associated with uveitis and diabetic macular edema (DME), as well as gene therapy. Dr. Steven Yeh, Associate Professor, Emory Eye Center, stated, “Suprachoroidal injections are a novel drug delivery approach with high selectivity for the retina and choroid.
- ACCESSWIRE•last month
Healthcare Companies Positioned in Major Markets
HENDERSON, NV / ACCESSWIRE / February 15, 2019 / Pain relief medicines are a massive market 30 billion doses of which are consumed each year in the US alone. Opioids like codeine and hydrocodone are also ...
- GlobeNewswire•2 months ago
Presentation of Clearside Biomedical’s Extension Study of PEACHTREE for XIPERE™ Exhibits Durability Following Second Dose
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that data from MAGNOLIA, an extension study of PEACHTREE, its pivotal Phase 3 trial of XIPERE™ (formerly “suprachoroidal CLS-TA”) in patients with macular edema associated with non-infectious uveitis, was presented by Pauline Merrill, MD during the winter symposium of the American Uveitis Society in Park City, UT. Dr. Merrill is a Partner at Illinois Retina Associates and Section Director of Uveitis in the Department of Ophthalmology at Rush University Medical Center.
- GlobeNewswire•3 months ago
Clearside Biomedical to Present at the 37th Annual J.P. Morgan Healthcare Conference
ALPHARETTA, Ga., Jan. 02, 2019 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- Simply Wall St.•3 months ago
Need To Know: Clearside Biomedical, Inc. (NASDAQ:CLSD) Insiders Have Been Buying Shares
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On the other hand, we'd be remiss not to mention Read More...
- GlobeNewswire•3 months ago
Clearside Biomedical Submits New Drug Application for XIPERE™ for the Treatment of Macular Edema Associated with Uveitis
Approximately one-third of these patients develop uveitic macular edema, a build-up of fluid in the macula, the area of the retina responsible for sharp, straight-ahead vision. Macular edema is the leading cause of vision loss and blindness in uveitis patients and can occur from uveitis affecting any anatomic location - anterior, intermediate, posterior or pan. If approved by the FDA, XIPERE would be the first therapy for macular edema associated with uveitis.
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of CLSD earnings conference call or presentation 8-Nov-18 1:30pm GMT
Q3 2018 Clearside Biomedical Inc Earnings Call
- GlobeNewswire•4 months ago
Report: Exploring Fundamental Drivers Behind ForeScout Technologies, GNC, Dova Pharmaceuticals, CymaBay Therapeutics, Adesto Technologies, and Clearside Biomedical — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Nov. 27, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- GlobeNewswire•4 months ago
Clearside Biomedical to Participate in Stifel 2018 Healthcare Conference
ALPHARETTA, Ga., Nov. 07, 2018 -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for.
- ACCESSWIRE•4 months ago
Today’s Research Reports on Stocks to Watch: Teladoc Health and Clearside
NEW YORK, NY / ACCESSWIRE / November 6, 2018 / Shares of Teladoc Health were in the red on Monday after its CFO and COO sold off a big stake of his shares. Shares of Clearside Biomedical were also in the red on disappointing trial results. One was that the company's COO and CFO, Mark Hirschhorn had sold over $700,000 worth of shares last Friday, which amounted to over 81% of his stake in the company.
- GlobeNewswire•4 months ago
Clearside Biomedical to Report Third Quarter 2018 Financial Results on Thursday, November 8, 2018 – Conference Call to Follow
Clearside Biomedical, Inc. (CLSD), a biopharmaceutical company dedicated to developing treatments that restore and preserve vision for people with serious eye diseases, announced today that its third quarter 2018 financial results will be released at approximately 7:00 a.m. ET on Thursday, November 8, 2018. Following the release, Clearside will host a live conference call and webcast at 8:30 a.m. ET to discuss its financial results and provide a general business and strategic review.
- Insider Monkey•4 months ago
Major Stock Movers: Inuvo, Clearside Biomedical, Cirrus Logic, and More
It’s Monday and oil futures are relatively stable despite the news that the U.S. is beginning to impose sanctions on Iran again. Among the stocks making substantial waves today include Inuvo Inc. (NYSE:INUV), Clearside Biomedical Inc. (NASDAQ:CLSD), Sysco Corporation (NYSE:SYY), STMicroelectronics N.V. (NYSE:STM), and Cirrus Logic Inc. (NASDAQ:CRUS). Let’s dig deeper into why each stock moved. In the financial world […]
- GlobeNewswire•4 months ago
Clearside Biomedical Announces SAPPHIRE Phase 3 Study of Combination Therapy in Retinal Vein Occlusion Did Not Meet Its Primary Endpoint
- Focusing Resources on Uveitis Program; NDA Filing Expected Fourth Quarter 2018 - - Company to Host Conference Call at 8:30 a.m. ET to Review the 8-Week Topline Data -.
